Spironolactone for Heart Failure
Arch Fam Med. 2000;9:281.
In a large randomized trial of patients with severe heart failure (left ventricular ejection fracture of no more than 0.35), at a mean follow-up of 2 years, patients in the group that received 25 mg of spironolactone had a relative risk of death of 0.70 (95% CI, 0.60-0.82; P<.001) compared with the group that received placebo. The patients who received spironolactone also had fewer hospital admissions and better cardiac function status. Gynecomastia or breast pain was reported by 10% of the men who received spironolactone. (N Engl J Med. 1999;341:709-717.)
|
